This article only represents the author's own views.
It has developed a promising weight-loss drug and is raking in revenues from an anti-cancer injection. But the latest earnings from Innovent Biologics Inc. (1801.HK) could not excite investors, despite some strong headline figures.
It turns out that the potentially game-changing obesity drug may not hit the market before the end of the year, dampening hopes for swift profits. Added to that, an outsized net loss and the sudden departure of the firm’s R&D chief also took the shine off half-year results.
您已阅读9%（557字），剩余91%（5454字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。